Pages that link to "Q33737691"
Jump to navigation
Jump to search
The following pages link to Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy (Q33737691):
Displaying 8 items.
- Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice. (Q48031560) (← links)
- Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment (Q49519966) (← links)
- ICBS 2017 in Shanghai-Illuminating Life with Chemical Innovation. (Q52574306) (← links)
- Alternative Splicing in the Hippo Pathway-Implications for Disease and Potential Therapeutic Targets. (Q52658016) (← links)
- Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability. (Q54978916) (← links)
- Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype. (Q54981975) (← links)
- Alternative Splicing in Apicomplexan Parasites (Q64258871) (← links)
- Development of Chemical Entities Endowed with Potent Fast-Killing Properties against Plasmodium falciparum Malaria Parasites (Q90363486) (← links)